Early observations and pilot data that first suggested a new direction
The modern era of cataract surgery began with Charles Kelman's introduction of phacoemulsification in 1967, which replaced large-incision extracapsular cataract extraction (ECCE) with ultrasonic lens emulsification through a small incision. Early phaco technology had high complication rates, but refinements in the 1980s and 1990s made it the dominant technique worldwide. The parallel evolution of foldable intraocular lenses (IOLs) enabled insertion through incisions under 3mm, dramatically reducing surgical trauma and recovery time. The shift from ECCE to phaco represented the first major paradigm change, reducing surgical time from 60+ minutes to under 20 minutes and enabling outpatient surgery.
Landmark RCTs and pivotal trials that established the evidence base
The development of multifocal and toric IOLs transformed cataract surgery from purely rehabilitative to refractive, aiming for spectacle independence. The ReSTOR multifocal IOL and the AcrySof Toric IOL gained FDA approval in 2005 and 2005-2006 respectively, supported by multicenter trials demonstrating high rates of spectacle independence and effective astigmatism correction. Extended depth of focus (EDOF) lenses like the Symfony (now Vivity) offered a continuous range of vision with fewer optical side effects than earlier multifocal designs. These premium IOL technologies proved that cataract surgery could simultaneously address presbyopia and astigmatism, fundamentally changing patient expectations and surgical planning.
Follow-up studies, subgroup analyses, and real-world validation
Femtosecond laser-assisted cataract surgery (FLACS) was introduced in 2010, promising improved precision in capsulotomy, lens fragmentation, and corneal incisions. However, the FEMCAT and FACT trials showed that while FLACS offered more precise capsulotomies, it did not significantly improve final visual outcomes compared to standard phacoemulsification, and was substantially more expensive. The light-adjustable lens (LAL, RxSight), FDA-approved in 2017, introduced a radically different approach: implanting a photosensitive IOL that could be adjusted postoperatively with UV light to fine-tune the refractive outcome, achieving significantly better uncorrected distance vision than conventional IOLs. New-generation trifocal lenses (PanOptix, Synergy) further expanded the range of premium IOL options.
Integration into clinical practice guidelines and recommendations
The American Academy of Ophthalmology and European Society of Cataract and Refractive Surgeons (ESCRS) provide comprehensive guidelines on IOL selection and surgical techniques. Current guidelines emphasize the importance of thorough preoperative biometry and patient counseling regarding premium IOL options, including realistic expectations about spectacle independence. NICE recommends standard phacoemulsification as the technique of choice and notes that femtosecond laser-assisted surgery has not demonstrated superiority in visual outcomes to justify its additional cost. Guidelines increasingly address the role of toric IOLs as the standard approach for patients with pre-existing corneal astigmatism greater than 1.0 diopter.
American Academy of Ophthalmology Preferred Practice Pattern - Cataract
Phacoemulsification is the preferred surgical technique. IOL selection should be individualized based on patient needs, biometry, and ocular surface health. Toric IOLs recommended for astigmatism >1.0D.
ESCRS Clinical Guidelines on Prevention and Treatment of Endophthalmitis
Intracameral cefuroxime at end of surgery reduces endophthalmitis risk. Updated IOL power calculation formulae recommended for improved refractive outcomes.
Now
Current standard of care and ongoing research directions
Cataract surgery is now the most commonly performed surgical procedure worldwide, with over 20 million procedures annually. Current innovation focuses on further reducing residual refractive error through AI-powered IOL power calculation, advanced biometry (swept-source OCT), and adjustable IOL technology. The light-adjustable lens is gaining market share as outcomes data matures. Cataract surgery combined with MIGS (minimally invasive glaucoma surgery) is increasingly performed as a combined procedure. Robotic-assisted cataract surgery is in early clinical trials. The field continues to push toward a zero-refractive-error target while expanding access in low- and middle-income countries where cataract remains the leading cause of blindness.
Does femtosecond laser-assisted cataract surgery produce better outcomes than standard phacoemulsification?+
Randomized trials including FEMCAT have not demonstrated a clinically meaningful improvement in visual outcomes with FLACS compared to standard phacoemulsification performed by experienced surgeons. FLACS does produce more precise capsulotomies, but this has not translated into better final vision. The significant additional cost has limited its adoption as routine practice.
What is the light-adjustable lens and how does it work?+
The RxSight light-adjustable lens (LAL) is a photosensitive silicone IOL that can be non-invasively adjusted after implantation using UV light treatments in the office. After the eye heals from surgery, the surgeon performs light treatments to adjust the lens power, then locks in the final prescription. The pivotal trial showed 92% of LAL patients achieved 20/20 or better uncorrected distance vision versus 62% with conventional IOLs.
How has IOL power calculation improved over time?+
IOL calculation has evolved from regression-based formulae (SRK, SRK/T) to vergence-based (Holladay, Hoffer Q, Haigis) to ray-tracing and AI-powered approaches (Hill-RBF, Kane formula, Barrett Universal II). Modern formulae combined with swept-source OCT biometry achieve target refraction within 0.5D in over 80% of eyes, compared to roughly 55% with older methods.
